SynAct Pharma’s board and management extend lock-up agreements
SynAct Pharma AB (“SynAct”) today announced that all members of its board and management have signed lock-up agreements for their shares in the company until June 30, 2022. In total the lock-up agreements correspond to more than 20 percent of the votes and capital in SynAct Pharma.The members of the board and management who have joined during the second half of 2021 have entered into new agreements whereas the others have extended their already existing lock-ups for a period of 6 months from the end of this year until end of June 2022. The lock-up prevents the selling of shares, except what